Khosla Ventures and Seventure Partners have driven Eligo Bioscience to a $20 million (€17 million) series A. The round equips Eligo to move its lead CRISPR-enabled, bacteria-killing candidate toward ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback